首页> 外文期刊>Journal of computer assisted tomography >A contrast agent delivery nomogram for hepatic spiral CT.
【24h】

A contrast agent delivery nomogram for hepatic spiral CT.

机译:肝脏螺旋CT的造影剂输送列线图。

获取原文
获取原文并翻译 | 示例
       

摘要

PURPOSE: A nomogram for hepatic spiral CT (SCT) was constructed based on randomization of patients into a prospective study using four different injection protocols. Its utility in a separate prospective randomized trial was subsequently evaluated in a new group of patients. METHODS: Thirty-nine patients randomized into four groups underwent SCT (Somatom-Plus S; 24 s exposure, 10 mm collimation, 10 mm/s) using 90 ml Omnipaque 240 (22 g I) at 2.5, 4, 5, or 6 ml/s. Peak and mean aortic and liver enhancement and time to peaks were measured and correlated with patients' age, weight, dose, rate, and contrast agent concentration, and a nomogram was constructed. In the validation experiment, 20 new patients were randomized to nomogram-guided and control groups for contrast dose administration during SCT. All patients underwent SCT (Somatom-Plus S; 32 s exposure, 10 mm collimation, 10 mm/s) using 90 ml Omnipaque 240 or 140 ml Hypaque 60 at 1.5-6 ml/s. Peak and mean aortic and liver enhancement and time to peaks were measured and correlated with patients' age, weight, dose, rate, and contrast agent concentration. Mean and peak aortic and hepatic enhancements were measured and rated by three blinded reviewers. RESULTS: Peak hepatic enhancement occurred 32 s after termination of contrast bolus administration in all groups. Correlation between the predicted and actual enhancement was very good (r = 0.7-0.9). Ninety-eight percent of the nomogram-guided group had optimal timing and utilized 10% less contrast agent than the control group. CONCLUSION: The phenomenon of peak hepatic enhancement occurring 32 s after the termination of contrast bolus regardless of injection rate may be of use in a nomogram for optimal contrast delivery for hepatic SCT.
机译:目的:建立肝螺旋CT(SCT)的列线图,是基于使用四种不同注射方案将患者随机分为一项前瞻性研究的。随后在一组新患者中评估了其在一项单独的前瞻性随机试验中的效用。方法:将39例随机分为四组的患者接受90、2.5、4、5或6的90 ml Omnipaque 240(22 g I)进行SCT(Somatom-Plus S; 24 s暴露,10 mm准直,10 mm / s)。毫升/秒测量峰值和平均主动脉和肝脏增强以及达到峰值的时间,并将其与患者的年龄,体重,剂量,比率和造影剂浓度相关联,并制作诺模图。在验证实验中,将20名新患者随机分配到列线图指导和对照组,以在SCT期间进行对比剂量管理。所有患者均以1.5-6 ml / s的速度使用90 ml的Omnipaque 240或140 ml的Hypaque 60进行SCT(Somatom-Plus S;暴露32 s,准直10 mm,10 mm / s)。测量峰值和平均主动脉和肝脏增强以及达到峰值的时间,并将其与患者的年龄,体重,剂量,比率和造影剂浓度相关。平均和峰值主动脉和肝脏的增强由三位盲审者进行测量和评估。结果:所有组在结束造影剂推注后32 s出现了峰值肝增强。预测增强效果与实际增强效果之间的相关性很好(r = 0.7-0.9)。诺模图引导组中有98%具有最佳时机,并且与对照组相比使用的造影剂少10%。结论:造影剂推注终止后32 s出现峰值肝增强现象,而与注射速率无关,这可能在诺模图中用于肝SCT最佳造影剂输送。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号